Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Empagliflozin in Paediatric Heart Failure
NCT06012266Phase 2Not yet recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of dapagliflozin, empagliflozin in heart failure (HF), sponsored by Lausanne University Hospital. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06012266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012266.